Resumen: Fanciulli and Wenning's review (Jan. 15 issue) on multiple-system atrophy is comprehensive and up to date. In it, the authors state that the open-label administration of gabapentin could ameliorate cerebellar symptoms in single cases of this disease. However, the cited reference describes a noticeable improvement in gait in one patient who received a diagnosis of olivopontocerebellar atrophy (OPCA) after a single dose of 400 mg of gabapentin and alleviation of dysarthria and oscillopsia in another patient with OPCA during long-term therapy with gabapentin. These patients could not have received a diagnosis of multiple-system atrophy, since neither had features of autonomic dysfunction. In contrast, gabapentin was found to cause generalized weakness and to worsen gait and dysarthria in three patients with multiple-system atrophy, forcing withdrawal of the drug... Idioma: Inglés DOI: 10.1056/NEJMc1501657 Año: 2015 Publicado en: NEW ENGLAND JOURNAL OF MEDICINE 372, 14 (2015), 1374 ISSN: 0028-4793 Factor impacto JCR: 59.558 (2015) Categ. JCR: MEDICINE, GENERAL & INTERNAL rank: 1 / 155 = 0.006 (2015) - Q1 - T1 Factor impacto SCIMAGO: 16.591 - Medicine (miscellaneous) (Q1)